Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report – Segmented By Treatment, Medication, Psychotherapy, Education or Training & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends, Growth & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 269
Pages: 145

MEA ADHD Therapeutics Market Size (2022 to 2027)

The Middle East and Africa ADHD Therapeutics Market is expected to reach USD 1.42 billion by 2027 from USD 0.91 billion in 2022, growing at a CAGR of 9.31% during the forecast period.

The healthcare industry is expected to be ruled by technology-driven innovation in the future. As a result, extensive research is being undertaken in every healthcare market sector, with precision medicine serving as the focal point.

ADHD children are more likely to develop a range of additional issues, such as clinical depression. In addition, due to their warped lifestyle and inability to control their urges, these children may develop long-term psychiatric disorders. As a result, it's vital to create effective ADHD therapies for children and teenagers. Furthermore, the growing focus of the medical community on the treatment of mental illnesses is expected to boost market growth.

The prevalence and incidence of attention-deficit hyperactivity disorder among adults and children in MEA are estimated to accelerate the market's growth during the forecast period. Furthermore, countries such as the United Arab Emirates (UAE) and Kuwait, where key companies are focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD), are expected to drive the Therapeutics for attention deficit hyperactivity disorder (ADHD) in MEA during the forecast period.

However, prescriptions are limited based on a patient's medical condition due to many contraindications and harmful effects of ADHD drugs, which is expected to slow revenue growth.

This research report on the MEA ADHD therapeutics market has been segmented and sub-segmented into the following categories:

By Medication:

  • Stimulants
  • Non-Stimulants

By Psychotherapy:

  • Behaviour Therapy
  • Cognitive Behavioural Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

By Education Or Training:

  • Parent Management Training
  • Social Skills Training
  • School-Based Interventions

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

During the forecast period, the demand for ADHD drugs in the MEA is expected to expand. The healthcare industry is working hard to provide viable treatment options for ADHD in children and adolescents. Because of the detrimental implications of ADHD, medical experts have decided to focus their efforts on finding new treatment alternatives.

A thorough examination of the regional market for ADHD therapies uncovers a host of factors that have influenced regional demand. In the UAE and Kuwait, attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by debilitating and pervasive impulsivity, hyperactivity, and inattention symptoms.


Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.) are a few of the prominent companies in the MEA ADHD therapeutics market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample